Article preview from IN VIVO - January, 2012
As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.
Article preview from IN VIVO - January, 2012
The Food and Drug Administration’s (FDA) approval of Edwards Lifesciences Corp.’s Sapien transcatheter aortic heart valve device in early November was certainly a landmark occasion for the US cardiovascular device industry. But the move was so widely anticipated, it was already old news by the time the Transcatheter Cardiovascular Therapeutics (TCT) conference rolled around less than a week later. At TCT, US physicians were treated to a number of detailed sessions on how to set up and operate a transcatheter aortic valve implantation (TAVI) program at their hospitals, with an emphasis on collaboration between multidisciplinary teams of physicians (including interventionalists, heart valve surgeons, and advanced imaging experts); but there were also several sessions in which physicians discussed how deeply this technology will/should penetrate US clinical practice over the next several months. Although TAVI offers a new treatment paradigm for valve disease patients, one that many believe could significantly expand the treatable patient population, there are still some important questions about this procedure that remain to be answered – such as whether TAVI’s higher stroke risk compared to valve replacement surgery will limit its usefulness outside of inoperable or high surgical risk patients, and how durable TAVI devices will prove to be over the long term.
Continued...
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
Comments